企業プロフィール
Genmab 株価・ニュース・カタリスト
- ティッカー:
- GMAB
- 取引所:
- NASDAQ
- セクター:
- Antibody Drugs
- 所在地:
- Copenhagen, Denmark
株価パフォーマンス
34.55 USD (-3.15%)
終値
最終更新: 2026年10月1日
14.6B USD
時価総額
株価変動の要因
2026年10月1日 時点で GMAB は 3.15% 下落し、$34.55 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Antibody-Focused Biotechnology Company
Genmab is a global biotechnology company focused on creating differentiated antibody therapeutics for cancer and other serious diseases. It combines internal antibody discovery, proprietary engineering platforms, clinical development, commercialization, and a large network of pharmaceutical partnerships.
Proprietary Antibody Technologies
The company's technology base includes DuoBody bispecific antibodies, HexaBody antibodies with enhanced complement activation, DuoHexaBody constructs, and HexElect conditional effector-function technology. These platforms are designed to generate new mechanisms of action and can support both wholly owned programs and partnered medicines.
Commercial and Co-Commercialized Medicines
Genmab's direct commercial portfolio includes EPKINLY/TEPKINLY, an epcoritamab-based bispecific antibody for B-cell malignancies, and Tivdak for cervical cancer. The company shares economics and commercialization responsibilities with partners in selected markets while retaining the ability to build its own global oncology organization.
Royalty-Based Portfolio
Antibodies created with Genmab technology support a significant royalty business. Products contributing to this model include DARZALEX, Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY, and BIZENGRI, providing diversified exposure across oncology, immunology, and rare disease without requiring Genmab to fund every commercial infrastructure independently.
Late-Stage Oncology Pipeline
The late-stage proprietary pipeline is led by Rina-S, an antibody-drug conjugate targeting folate receptor alpha, and petosemtamab, an EGFRxLGR5 bispecific antibody added through the acquisition of Merus. Epcoritamab is also being developed across additional lymphoma settings and treatment lines, making lifecycle expansion an important part of the portfolio.
今後のカタリスト
- Phase 3 RAINFOL-02 data for Rina-S in platinum-resistant ovarian cancer during 2026.
- Phase 3 data from one or both LiGeR-HN studies of petosemtamab in head and neck squamous cell carcinoma during 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。